Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies. The company has two product candidates that are currently in clinical development, and one in pre-clinical evaluation. iSONEP iSONEP is the ocular formulation of sonepcizumab, a humanized monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P). Sphingomab is the original mouse version of this monoclonal antibody. iSONEP is administered by intravitreal injection, and has demonstrated multiple mechanisms of action in ocular models of disease, including anti-angiogenesis, anti-inflammatory, anti-fibrotic and anti-vascular permeability. ASONEP ASONEP is the systemic formulation of sonepcizumab. In 2010, the company completed a Phase 1 clinical trial in which ASONEP was evaluated in very late-stage cancer patients. In that trial, ASONEP was well tolerated at all dose-levels ranging from 1 mg/kg to 24 mg/kg., other than minor infusion-related reactions observed at the highest dose. In collaboration with Beth Israel Deaconess Medical Center, the company has demonstrated efficacy of ASONEP in preclinical models of a form of human kidney cancer called renal cell carcinoma. Lpathomab Lpathomab, a pre-clinical product candidate, is a mAb against lysophosphatidic acid (LPA), a key bioactive lipid that has been recognized as a significant promoter of cancer-cell growth and metastasis in a range of tumor types. The company has selected the clinical candidate mAb from among three humanized mAbs that inhibit LPA. These mAbs were tested against each other in various models of human disease to determine which mAb would be most likely to succeed in clinical trials. Intellectual-Property The company’s intellectual-property position in the bioactive-lipid area includes 82 issued patents, including 53 foreign patents, and 114 patent applications, including 88 foreign patent applications. Government Regulation The company is required to submit the results of its preclinical tests, together with manufacturing information and analytical data, to the U.S. Food and Drug Administration as part of an Investigational New Drug Application, which must become effective before the company may begin human clinical trials.
lpath inc-class a (LPTN:NASDAQ CM)
4025 Sorrento Valley Boulevard
San Diego, CA 92121
|No competitor information is available for LPTN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact LPATH INC-CLASS A, please visit www.lpath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.